Valuation: Iqvia Holdings

Market Cap 43.93B 39.05B 36.19B 32.93B 62.14B 4,169B 63.14B 435B 171B 2,176B 165B 161B 6,936B P/E 2026 *
34x
P/E 2027 * 27.2x
Enterprise Value 57.8B 51.38B 47.62B 43.33B 81.76B 5,486B 83.07B 572B 224B 2,863B 217B 212B 9,126B EV / Sales 2026 *
3.32x
EV / Sales 2027 * 3.1x
Free-Float
62.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 03/10/2016
Director of Finance/CFO 51 28/02/2026
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 68 05/02/2015
Chairman 64 03/10/2016
Director/Board Member 69 03/10/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+2.60% - - 43.93B
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.56%-1.67%+43.33%+85.71% 41.32B
Weighted average by Cap. -1.94%-1.21%+43.56%+88.58%

Financials

2026 *2027 *
Net sales 17.42B 15.48B 14.35B 13.05B 24.63B 1,653B 25.03B 172B 67.62B 863B 65.36B 63.97B 2,750B 18.47B 16.42B 15.22B 13.85B 26.13B 1,753B 26.55B 183B 71.72B 915B 69.32B 67.84B 2,916B
Net income 1.3B 1.16B 1.07B 978M 1.85B 124B 1.87B 12.92B 5.06B 64.6B 4.9B 4.79B 206B 1.61B 1.43B 1.33B 1.21B 2.28B 153B 2.32B 15.97B 6.26B 79.88B 6.05B 5.92B 255B
Net Debt 13.87B 12.33B 11.43B 10.4B 19.62B 1,316B 19.93B 137B 53.86B 687B 52.05B 50.95B 2,190B 13.26B 11.78B 10.92B 9.94B 18.75B 1,258B 19.05B 131B 51.48B 657B 49.75B 48.69B 2,093B
Logo Iqvia Holdings
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (40.6%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (4.9%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (47.5%), Europe and Africa (31.8%) and Asia/Pacific (20.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Iqvia Holdings